9

r

d

e

p

r

e

s

s

iv

e

dis

o

r

d

e

r

s

,

1

8

1

9

t

,

1

8

2

0

t

,

1

8

2

1

t

fo

r

dia

b

e

t

e

s

,

2

2

2

6

t

fo

r

h

o

t

flu

s

h

e

s

,

1

0

3

6

fo

r

O

C

D

,

1

7

6

0

fo

r

p

a

nic

dis

o

r

d

e

r

,

1

7

4

8

fo

r

S

A

D

,

1

7

5

2

t

e

r

a

t

o

g

e

nic

e

ffe

c

t

s

,

9

7

3

t

fo

r

v

a

s

o

mo

t

o

r

s

ymp

t

o

m

s

,

1

0

3

6

t

P

a

r

o

x

e

t

i

n

e

m

e

s

yl

a

t

e

(

B

ri

s

d

e

l

l

e

)

,

1

0

3

6

t

P

A

S

(

s

e

e

P

-

a

m

i

n

o

s

a

l

i

c

yl

i

c

a

c

i

d

(

P

A

S

)

)

P

a

t

i

r

o

m

e

r

,

fo

r

h

yp

e

r

k

a

l

e

m

i

a

,

5

8

6

Paxil (see Paroxetine)

Pazopanib, 470t, 1977, 1990

and hypertension, 1990

PCP (see Phencyclidine (PCP))

PCV (see Conjugated pneumococcal vaccine (PCV))

Pedialyte, 2160

Pediarix, 1356t

Pediatric amino acid formulations (PAAFs), 2150–2151

Pegaptanib, 1169

PEG-asparaginase, 2017t

Pegaspargase, 469t

Peginesatide, 616

Peginterferon, 469t

Pegloticase, 918

Pegylated interferon (PegIFNs), 1677

Pembrolizumab, 469t

Pemetrexed, 469t

for NSCLC, 2062t, 2063t

Pemirolast, 1165

Penciclovir cream (Denavir), 1650

Penems, 1332t

Penicillin, 47–48, 942t, 1550

adverse effects of, 1332t

for aerobic gram-positive cocci, 1326t

allergy, 684–685

for anaerobes, 1328t

cross-reactivity between carbapenems and monobactams, 685

desensitization, 698

drug eruptions and, 823

for endocarditis, 1390

and hypokalemia, 583t

renal failure, dosing of drugs, 673–674

for RMSF, 1725

for skin and soft tissue infections, 1549, 1550, 1552

skin testing procedure, 685t

for UTI, 1497t

Penicillin G, 1326t, 1394, 1720, 2131t

for CAPD-associated peritonitis, 1476t

for CNS infections, 1373t

dosing of, 1337t

for enterococcal endocarditis, 1397t

for GBS infection, 995

for sepsis, 2186t

for syphilis, 1519–1520t

Penicillin V, 1326t

Pentacel, 1356t

Pentamidine, 1603

Pentasa (see Mesalamine)

Pentobarbital, 2199t

Pentostatin, 469t, 1991t

Pentoxifylline, 168

for ASD, 1856

Peppermint oil capsules, 535

Peramivir (Rapivab), 1656

Perampanel, 1279t, 1281

for seizures, 1286t

Perindopril, 153t

Permethrin, 1704t

liquid rinse, 1711

for scabies, 1705t

Perphenazine, 1267, 1789t, 1797t, 1799t

for schizophrenia, 1785, 1790, 1792

Pertuzumab, 469t

Petrolatum, 1712

P-glycoprotein/ABCBI inhibitors, 914t

Phenazopyridine, 1492

Phencyclidine (PCP), 1885

dissociative drug, 1885

and lactation, 1003t

for schizophrenia, 1783, 1783t

Phendimetrazine, 762

Phenelzine, 1748

Phenergan (see Promethazine)

Phenformin, 1140

Phenidone, 1003t

Pheniramine, 439t

Phenobarbital, 942t, 1279t, 2131t

for febrile seizures, 1295

for opioid dependence, 1881

for SE, 1300

sedative-hypnotics, 1882

for seizures, 1284t, 2191–2192

Phenolates, 1626

Phenothiazines, 1789t, 2262t

for NVP, 975, 976t

Phenoxybenzamine, 2261t

Phentermine/topiramate (Qsymia), 762, 763t

Phentolamine, 2266

Phenylbutazone, 942t

Phenylephrine (Neo-Synephrine; Sudafed PE), 434t, 2207t

for postoperative cardiac failure, 363t

for rhinitis, 437

for septic shock, 371

Phenytoin, 41, 42–43, 55, 58t, 484, 485, 486, 579, 942t, 988, 1279t, 2131t, 2218, 2261t

gum hyperplasia and, 1289

for HAV, 1688

hypersensitivity to, 1295–1296

initiation and dosage of, 1287

intoxication with, 1288

neurotoxicity from, 1289

for nocturnal leg cramps, 173

pharmacokinetics of, 1288

renal failure, dosing of drugs, 676, 676f

in SE, 1299

for seizures, 1284t, 1287–1290, 2192

teratogenic effects, 973t

Phosphates, 27, 589t, 591

-binding agents, 620t

enema, 2159t

Phosphodiesterase inhibitors

androgen deprivation therapy, 2097

PDE-4, 841, 843

PDE-5, 2264–2265

Phospholine Iodide, 1152–1153

Phosphorus, 968

Phytoestrogens, 1030

Picaridin, 1721

Pilocarpine, 1152, 1153, 1158

Pimavanserin, 1267

Pimecrolimus, 819

Pindolol, 1272, 2261t

Pioglitazone, 942t, 1066, 1123, 1124, 1125

for HF, 275

for type 2 diabetes, 1134

Piperacillin, 674

Piperacillin-tazobactam, 1338t

for anaerobes, 1328t

for chorioamnionitis, 996

for cystic fibrosis, 461t

and hypokalemia, 583t

for skin and soft tissue infections, 1550

for UTI, 1497t

Piroxicam, 870t, 887, 888t

Pitavastatin, 110t, 116, 117t, 120t

Platinum-based therapies, 2064

Pneumococcal conjugate vaccine, 2164

Pneumococcal polysaccharide vaccine, 419

Pneumococcal vaccine, 1409

Pneumovax, 1360

Podofilox, 1532

Podophyllin, 1532

Polyethylene glycol, 2158, 2159t

Polymerase inhibitors, 1686

Polymyxin B, 1476t

Polyvinylpyrrolidone, 1975

Pomalidomide, 470t, 2038

Ponatinib, 470t

Posaconazole, 120t, 128, 1624t, 1625, 1626t, 1628, 1636, 1639

adverse effects of, 1334t

dosing of, 1338t

Potassium, 1603, 1991

and children, 2140t

and dyspepsia, 487

GERD and, 503t

and induction therapy, 1612

loss due to diarrhea, 2142

maintenance doses of, 2141

in oral electrolyte solutions, 2161t

for pernicious anemia, 1935

and renal dysfunction, 1991

and respiratory alkalosis, 1672

and TLS, 2027

in WHO formula, 2160

Potassium bicarbonate, 1916

Potassium chloride, 584

for metabolic alkalosis, 564

Potassium dichromate, 822t

Potassium hydroxide (KOH), 1626

Potassium iodide, 1624t

Potassium-sparing diuretics, 148, 150

p. 2311

p. 2312

Potassium supplementation

doses of, 279

for HF, 278–279

Povidone iodine, 1624t

PPIs (see Proton-pump inhibitors (PPIs))

Pralatrexate, 469t

Pramipexole, 1193, 1250t, 1254, 1254t, 1267, 1269

Pramlintide, 1129

Prasugrel, 244, 246–247t

and aspirin, for ACS, 242t

Pravastatin, 41, 46t, 110t, 116, 120t, 125

Praziquantel, 1705t, 1710

for flukes, 1704t

side effects of, 1710

Prazosin, 157t, 923, 2261t

in patients with CKD, 617

for PTSD, 1754

for Raynaud’s disease, 171

Precef (see Ceforanide)

Prednisolone, 721, 925, 1654

Prednisolone acetate, 1165–1166

Prednisone, 721–722, 925, 2037t, 2040t, 2042

for AECOPD, 1409

for ALL, 2017t

for COPD, 424

cryptococcal disease, 1641

for drug eruptions, 821, 823

for HL, 2041

for hypercalcemia, 591

for ophthalmopathy, 1066–1067

for prostate cancer, 2094

for radiographic opacities and hypoxemia, 326

for rhinitis, 442

for T-cell lymphomas, 2020t

Pregabalin (Lyrica), 1180, 1181t, 1187t, 1194t, 1195, 1271t, 1272, 1279t, 1281

androgen deprivation therapy, 2097

for diabetes, 1145

for PHN, 1654

for SAD, 1752

for seizures, 1284t, 1286

for vasomotor symptoms, 1036t

Premarin (see Conjugated equine estrogen)

Premphase, 1033t

Prempro, 1033t

Prevnar, 1360

Prilocaine, 1177t

Primaquine, 1696, 1699t

Primaxin (see Imipenem-cilastatin)

Primidone, 942t, 1271t, 1272

Pristiq (see Desvenlafaxine)

Privine (see Naphazoline)

PRL (see Prolactin (PRL))

Probenecid, 43, 917

Probiotics

for CDAD, 1466

for gastroenteritis, 2161

for infectious diarrhea, 1449

Procainamide, 325

for tachycardia, 1802

for WPW, 320

Procaine, 1177t

Procarbazine (Matulane), 470t, 1982t, 1985, 1998

encephalopathic toxicity of, 1985

for HL, 2041

neurotoxicity of, 1985t

Prochieve (see Progesterone vaginal gel)

Prochlorperazine (Compazine), 472t, 1240

for end-of-life care, 89

for NVP, 975, 976t

for PONV, 478t

Procyclidine, 1800t

Proferrin-ES, heme iron product, 613

Progesterone, 965, 980

in assisted reproductive technology, 965t

GERD and, 503t

vaginalsuppository, 1033t

Progesterone vaginal gel (Prochieve, Crinone), 1033t

Progestin-bisphosphonate, 1022

Progestins (Medroxyprogesterone)

for endometriosis, 1019

for polycystic ovary syndrome, 1012t

Prokinetic agents, 508

for GER, 2163, 2163t

Prolactin (PRL), 980, 999

Promethazine (Phenergan), 91, 468t, 472t

for NVP, 975, 976t

for PONV, 478t

Prometrium (see Micronized progesterone)

Propafenone, 315

for WPW, 320

Propionic acid, 1626

Propofol, 1213

for pediatric intubation, 2200t

Propranolol, 550, 1241, 1271–1272, 1271t, 2131t, 2261t

for Akathisia, 1799, 1800t

drug interaction with smoking, 1906t

in hypertension, 159t

for hyperthyroidism, 1059t

for MI, 253

for PTSD, 1754

Proprotein convertase subtilisin/kexin type 9 (PCSK9)

adverse effects of, 131

clinical pearls, 131

efficacy, 129–130

mechanism of action, 129, 130f

pharmacokinetics/pharmacodynamics of, 130–131

place in therapy, 131

Propylthiouracil (PTU), 1042, 1059t

and hepatitis, 1062

for thyroid storm, 1067

ProQuad, 1356t, 1362, 1363

ProSol, 794t

Prostacyclin, 220

Prostaglandins

analogs, 1151

GERD and, 503t

inhibitors, 591

Protamine, 187

Protein C, 1032

Protein S, 1032

Proton-pump inhibitors (PPIs), 484–486, 493t, 977, 1215–1216, 1216t, 1975

adverse effects of, 485

and AIN, 645

for ALF, 1672

CDAD and, 1467

CYP2C19 interaction, 485

for GER, 2162, 2163t

for GERD, 508

and H2RA, in combination, 508

for preventing SRMB, 515

for upper GI bleeding, 512, 516t

Prozac (see Fluoxetine)

Pseudoephedrine (Sudafed), 434, 434t, 437–438, 1766

Psoralens plus ultraviolet A light (PUVA) therapy, 836t, 838–841

PTU (see Propylthiouracil (PTU))

PUVA therapy (see Psoralens plus ultraviolet A light (PUVA) therapy)

Pyrantel pamoate

for enterobiasis, 1703t

for pinworm, 1708

Pyrazinamide, 53

dosing of, 1338t

for tuberculosis, 1429t, 1433

Pyrethrin, 1711

Pyridoxine (vitamin B6

), 1261t

for NVP, 975, 976t

for PMS, 1024

Pyrilamine, 1015

Pyrimethamine

plus clindamycin, 1604–1605

and leucovorin plus azithromycin, 1607

for OIs, 1598

plus sulfadiazine, 1604–1605

toxicities associated with, 1606

QQ

s

y

m

i

a

(

s

e

e

P

h

e

n

t

e

r

m

i

n

e

/

t

o

p

i

r

a

m

a

t

e

)

Q

u

a

d

r

a

c

e

l

,

1

3

5

6

t

Q

u

a

d

ri

v

a

l

e

n

t

i

n

t

r

a

n

a

s

a

l

l

i

v

e

a

t

t

e

n

u

a

t

e

d

i

n

fl

u

e

n

z

a

v

a

c

c

i

n

e

(

L

A

I

V4

)

,

1

3

6

1

Q

u

az

e

p

a

m

(

D

o

r

a

l

)

,

1

7

3

7

t

fo

r

tr

e

a

tme

nt

o

f

in

s

o

mnia

,

1

7

6

7

t

Q

u

e

t

i

a

p

i

n

e

(

S

e

r

o

q

u

e

l

)

,

1

7

3

9

,

1

7

9

7

t

,

1

7

9

9

t

fo

r

a

c

ut

e

ma

nia

,

1

8

4

4–

1

8

4

5

,

1

8

4

5

t

fo

r

a

g

it

a

t

e

d

b

e

h

a

v

io

r

s

,

2

2

4

4

fo

r

b

ip

o

la